文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

接受连续性肾脏替代治疗患者枸橼酸蓄积发生时间相关的临床与生物学特征

Clinical and biological profiles associated with the time of occurrence of citrate accumulation in patients receiving continuous renal replacement therapy.
PubMed 文献 · Crit Care · 2025-09-26
一句话结论在RCA-CRRT患者中,枸橼酸蓄积发生率为3.7%,91%发生在启动后24小时内,启动时高乳酸和严重代谢性酸中毒提示即时枸橼酸蓄积风险。

这项在法国里昂9个ICU开展的回顾性多中心观察研究纳入2020年1月至2022年1月接受RCA-CRRT的2080例患者,76例(3.7%)发生枸橼酸蓄积,其中69例(91%)在CRRT启动后24小时内发生(初始CA),7例(9%)在24小时后发生(迟发型CA)。初始CA组与迟发型CA组仅CRRT启动时乳酸水平有差异(10 mmol/l [4.6-16] vs 1.4 mmol/l [1-3.8],p=0.006)。初始CA组中39例(57%)在6小时或更短时间内出现CA征象(即时CA)。乳酸和pH预测即时枸橼酸蓄积的AUC分别为0.75 [0.62-0.87]和0.74 [0.62-0.85],最佳截断值分别为10.6 mmol/L和7.14。CA患者ICU死亡率为97%,全队列为55%。

要点

  • RCA-CRRT患者枸橼酸蓄积发生率3.7%(76/2080),其中91%(69例)发生在CRRT启动后24小时内。
  • 初始CA组CRRT启动时乳酸为10 mmol/l [4.6-16],迟发型CA组为1.4 mmol/l [1-3.8],两组差异p=0.006。
  • 初始CA组57%(39例)在6小时或更短时间内出现CA征象,43%(30例)在6至24小时之间出现。
  • 乳酸预测即时枸橼酸蓄积AUC为0.75 [0.62-0.87],最佳截断值10.6 mmol/L;pH的AUC为0.74 [0.62-0.85],最佳截断值7.14。
  • CA患者ICU死亡率为97%,全队列为55%。

适用人群与场景

  • 法国里昂9个ICU中2020年1月至2022年1月接受RCA-CRRT的2080例未经选择的危重患者。

诊断标准与关键阈值

  • 枸橼酸蓄积定义为总钙与离子钙比值(tCa/iCa)≥ 2.3,并伴有低钙血症和代谢性酸中毒。
  • 初始CA定义为CRRT启动后24小时内发生,迟发型CA定义为24小时后发生;即时CA定义为初始CA组中6小时或更短时间内出现CA征象。

红旗征与不能漏的情况

  • CRRT启动时严重代谢性酸中毒伴高乳酸血症是识别即时枸橼酸蓄积风险最相关的标志物,应鼓励密切监测tCa/iCa比值。

研究设计与关键结果

  • 回顾性多中心观察研究,9个ICU,纳入2080例接受RCA-CRRT的危重患者,76例(3.7%)发生枸橼酸蓄积。
  • 69例(91%)为初始CA(24小时内),7例(9%)为迟发型CA(24小时后)。
  • 初始CA组与迟发型CA组仅CRRT启动时乳酸水平有差异:10 mmol/l [4.6-16] vs 1.4 mmol/l [1-3.8],p=0.006。
  • 初始CA组中39例(57%)在6小时或更短时间内出现CA征象(即时CA),30例(43%)在6至24小时之间出现。
  • 初始CA患者首个24小时内乳酸水平显著升高、去甲肾上腺素需求恶化、tCa/iCa比值持续升高、凝血酶原时间缩短、转氨酶升高。
  • 即时CA组与早期CA组相比,CRRT启动时乳酸浓度更高、代谢性酸中毒更严重,其他标志物无显著差异。
  • 乳酸预测即时枸橼酸蓄积的AUC为0.75 [0.62-0.87],最佳截断值10.6 mmol/L;pH的AUC为0.74 [0.62-0.85],最佳截断值7.14。
  • CA患者ICU死亡率为97%,全队列为55%。

证据类型、等级与局限

  • 证据类型:回顾性、多中心观察研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于接受RCA-CRRT的危重患者,CRRT启动时严重代谢性酸中毒伴高乳酸血症提示即时枸橼酸蓄积风险,作者认为应鼓励密切监测tCa/iCa比值。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Citrate accumulation (CA) is a feared complication in critically ill patients undergoing regional citrate anticoagulation (RCA) for continuous renal replacement therapy (CRRT). This study aimed to describe the characteristics of patients presenting CA within a large cohort of unselected critically ill patients receiving RCA-CRRT depending on the time of occurrence of CA after CRRT initiation.

METHODS: This retrospective, multicenter observational study performed in nine intensive care units (ICU) in Lyon, France, included patients treated with RCA-CRRT between January 2020 and January 2022. CA was defined by a total to ionized calcium ratio (tCa/iCa) ≥ 2.3 associated with hypocalcemia and metabolic acidosis.

RESULTS: Among 2080 patients, 76 (3.7%) developed CA: 69 (91%) experienced CA within 24 h after CRRT initiation (initial CA) and 7 (9%) after 24 h (late-onset CA). Only lactate levels at CRRT initiation differed between patients with initial CA and those with late-onset CA (10 mmol/l [4.6-16] vs 1.4 mmol/l [1-3.8], p = 0.006 respectively). In the initial CA group, 39 (57%) exhibited signs of CA within 6 h or less (immediate CA) and 30 (43%) showed signs of CA between 6 and 24 h. Over the first 24 h, patients with initial CA presented a marked increase in lactate levels, worsening norepinephrine requirements, persistent elevation of the tCa/iCa ratio, decrease in prothrombin time, and increase in transaminases. Patients with immediate CA showed higher lactate concentration and more severe metabolic acidosis at CRRT initiation compared to patients with early CA whereas other markers did not differ significantly between the two groups. The area under the Receiver Operating Characteristic curve of lactate and pH for predicting immediate citrate accumulation were 0.75 [0.62 - 0.87] and 0.74 [0.62 - 0.85] respectively, with optimal cutoff values of 10.6 mmol/L and 7.14 respectively. The ICU mortality rate among patients with CA was 97% compared to 55% in the whole cohort.

CONCLUSIONS: CA is a rare phenomenon in patients under RCA-CRRT. Severe metabolic acidosis with hyperlactatemia at CRRT initiation is the most relevant marker to identify patients at risk of immediate CA and should encourage close monitoring of tCa/iCa ratio.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Bidar F, Chardon N, Darnajoux Q, et al. Clinical and biological profiles associated with the time of occurrence of citrate accumulation in patients receiving continuous renal replacement therapy. Crit Care. 2025. PMID: 41013710. doi:10.1186/s13054-025-05648-5

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。